These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33074019)

  • 1. Anticalin® proteins: from bench to bedside.
    Deuschle FC; Ilyukhina E; Skerra A
    Expert Opin Biol Ther; 2021 Apr; 21(4):509-518. PubMed ID: 33074019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural plasticity in the loop region of engineered lipocalins with novel ligand specificities, so-called Anticalins.
    Achatz S; Jarasch A; Skerra A
    J Struct Biol X; 2022; 6():100054. PubMed ID: 34988429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticalins small engineered binding proteins based on the lipocalin scaffold.
    Gebauer M; Skerra A
    Methods Enzymol; 2012; 503():157-88. PubMed ID: 22230569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins.
    Richter A; Eggenstein E; Skerra A
    FEBS Lett; 2014 Jan; 588(2):213-8. PubMed ID: 24239535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities.
    Skerra A
    FEBS J; 2008 Jun; 275(11):2677-83. PubMed ID: 18435758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The menagerie of human lipocalins: a natural protein scaffold for molecular recognition of physiological compounds.
    Schiefner A; Skerra A
    Acc Chem Res; 2015 Apr; 48(4):976-85. PubMed ID: 25756749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticalin
    Rothe C; Skerra A
    BioDrugs; 2018 Jun; 32(3):233-243. PubMed ID: 29748739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Anticalins': a new class of engineered ligand-binding proteins with antibody-like properties.
    Skerra A
    J Biotechnol; 2001 Jun; 74(4):257-75. PubMed ID: 11526907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystallographic analysis of an "anticalin" with tailored specificity for fluorescein reveals high structural plasticity of the lipocalin loop region.
    Korndörfer IP; Beste G; Skerra A
    Proteins; 2003 Oct; 53(1):121-9. PubMed ID: 12945055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial design of an Anticalin directed against the extra-domain b for the specific targeting of oncofetal fibronectin.
    Gebauer M; Schiefner A; Matschiner G; Skerra A
    J Mol Biol; 2013 Feb; 425(4):780-802. PubMed ID: 23238252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipocalins as a scaffold.
    Skerra A
    Biochim Biophys Acta; 2000 Oct; 1482(1-2):337-50. PubMed ID: 11058774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticalin®-based therapeutics: Expanding new frontiers in drug development.
    Morales-Kastresana A; Siegemund M; Haak S; Peper-Gabriel J; Neiens V; Rothe C
    Int Rev Cell Mol Biol; 2022; 369():89-106. PubMed ID: 35777866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-guided engineering of Anticalins with improved binding behavior and biochemical characteristics for application in radio-immuno imaging and/or therapy.
    Eggenstein E; Eichinger A; Kim HJ; Skerra A
    J Struct Biol; 2014 Feb; 185(2):203-14. PubMed ID: 23542582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMR structure and dynamics of the engineered fluorescein-binding lipocalin FluA reveal rigidification of beta-barrel and variable loops upon enthalpy-driven ligand binding.
    Mills JL; Liu G; Skerra A; Szyperski T
    Biochemistry; 2009 Aug; 48(31):7411-9. PubMed ID: 19603796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection and characterization of Anticalins targeting human prostate-specific membrane antigen (PSMA).
    Barinka C; Ptacek J; Richter A; Novakova Z; Morath V; Skerra A
    Protein Eng Des Sel; 2016 Mar; 29(3):105-15. PubMed ID: 26802163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticalins as an alternative to antibody technology.
    Schlehuber S; Skerra A
    Expert Opin Biol Ther; 2005 Nov; 5(11):1453-62. PubMed ID: 16255649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of an artificial receptor protein ("anticalin") based on the human apolipoprotein D.
    Vogt M; Skerra A
    Chembiochem; 2004 Feb; 5(2):191-9. PubMed ID: 14760740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An engineered lipocalin that tightly complexes the plant poison colchicine for use as antidote and in bioanalytical applications.
    Barkovskiy M; Ilyukhina E; Dauner M; Eichinger A; Skerra A
    Biol Chem; 2019 Feb; 400(3):351-366. PubMed ID: 30517073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis of Alzheimer
    Eichinger A; Rauth S; Hinz D; Feuerbach A; Skerra A
    Biol Chem; 2022 Apr; 403(5-6):557-571. PubMed ID: 35355502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticalins in drug development.
    Schlehuber S; Skerra A
    BioDrugs; 2005; 19(5):279-88. PubMed ID: 16207069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.